Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course

Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. Wi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiří Beran, Marián Špajdel, Jiří Slíva
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	inosine pranobex methisoprinol isoprinosine COVID-19 SARS-CoV-2 lymphopenia Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/df670267d08347da830983209ffe995c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:df670267d08347da830983209ffe995c
record_format	dspace
spelling	oai:doaj.org-article:df670267d08347da830983209ffe995c2021-11-25T19:13:44ZInosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course10.3390/v131122461999-4915https://doaj.org/article/df670267d08347da830983209ffe995c2021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4915/13/11/2246https://doaj.org/toc/1999-4915Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. With the emergence of SARS-CoV-2, new and existing drugs have been intensively evaluated for their potential as COVID-19 medication. Due to its potent immunomodulatory properties, inosine pranobex, an orally administered drug with pleiotropic effects, can, during early treatment, alter the course of the disease. We describe the action of inosine pranobex in the body and give an overview of existing evidence collected to support further efforts to study this drug in a rigorous clinical trial setup.Jiří BeranMarián ŠpajdelJiří SlívaMDPI AGarticleinosine pranobexmethisoprinolisoprinosineCOVID-19SARS-CoV-2lymphopeniaMicrobiologyQR1-502ENViruses, Vol 13, Iss 2246, p 2246 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	inosine pranobex methisoprinol isoprinosine COVID-19 SARS-CoV-2 lymphopenia Microbiology QR1-502
spellingShingle	inosine pranobex methisoprinol isoprinosine COVID-19 SARS-CoV-2 lymphopenia Microbiology QR1-502 Jiří Beran Marián Špajdel Jiří Slíva Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
description	Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. With the emergence of SARS-CoV-2, new and existing drugs have been intensively evaluated for their potential as COVID-19 medication. Due to its potent immunomodulatory properties, inosine pranobex, an orally administered drug with pleiotropic effects, can, during early treatment, alter the course of the disease. We describe the action of inosine pranobex in the body and give an overview of existing evidence collected to support further efforts to study this drug in a rigorous clinical trial setup.
format	article
author	Jiří Beran Marián Špajdel Jiří Slíva
author_facet	Jiří Beran Marián Špajdel Jiří Slíva
author_sort	Jiří Beran
title	Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
title_short	Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
title_full	Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
title_fullStr	Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
title_full_unstemmed	Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course
title_sort	inosine pranobex deserves attention as a potential immunomodulator to achieve early alteration of the covid-19 disease course
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/df670267d08347da830983209ffe995c
work_keys_str_mv	AT jiriberan inosinepranobexdeservesattentionasapotentialimmunomodulatortoachieveearlyalterationofthecovid19diseasecourse AT marianspajdel inosinepranobexdeservesattentionasapotentialimmunomodulatortoachieveearlyalterationofthecovid19diseasecourse AT jirisliva inosinepranobexdeservesattentionasapotentialimmunomodulatortoachieveearlyalterationofthecovid19diseasecourse
_version_	1718410186420387840

Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course

Ejemplares similares